Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Obstetrics and Gynecology Reports
Erschienen in: Current Obstetrics and Gynecology Reports 3/2020

25.06.2020 | Care for the Transgender Patients (C Ferrando, Section Editor)

Fertility Preservation for the Transgender Individual

verfasst von: Viji Sundaram, Evelyn Mok-Lin

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to update readers on recent evidence in order to counsel and guide clinical management of individuals with gender dysphoria seeking fertility preservation (FP).

Recent Findings

Relevant topics include a discussion of the consistent desire for children in transgender people despite a low utilization rate of FP services, animal models, and human histology depicting the effect of gender-affirming treatment (GAT) on the gonads, varied time for resumption of menses, and start of ovarian stimulation upon discontinuing testosterone (T) in transmen, feasible clinical and experimental options for FP in transgender males and females, worsening dysphoria, and recommended methods to mitigate symptoms, and lastly a short discussion of changes in legislation providing increased insurance coverage of medically indicated FP for transpatients.

Summary

FP is an important option for transgender patients who desire to retain the ability to become genetic parents. While controlled ovarian stimulation for oocyte or embryo cryopreservation is the standard-of-care for transmen, unique considerations must be made in this population. Recent literature has highlighted the ability of transmen to have viable oocytes and pregnancies despite a history of T use, suggesting that the window of genetic parentage does not close with the start of GAT. FP for transwomen requires ejaculation or extraction with sperm cryopreservation; options for prepubertal transwomen are only in nascent phases. Research is rapidly evolving though many questions remain unanswered. The harmonization of advances in assisted reproduction with legislation advocating for transgender rights will continue to reach new peaks in the coming years.
Literatur
1.
Diagnostic & Statistical Manual of Mental Disorders. In Arlington, VA: American Psychiatric Publishing; 2013.
2.
3.
Wiepjes CM, Nota NM, de Blok CJM, Klaver M, de Vries ALC, Wensing-Kruger SA, et al. The Amsterdam cohort of gender dysphoria study (1972–2015): trends in prevalence, treatment, and regrets. J Sex Med. 2018 Apr;15(4):582–90.PubMed
4.
Zucker KJ. Epidemiology of gender dysphoria and transgender identity. Sex Health. 2017;14(5):404.PubMed
5.
Fielding J, Bass C. Individuals seeking gender reassignment: marked increase in demand for services. BJPsych Bull. 2018 Oct;42(5):206–10.PubMedPubMedCentral
6.
Access to fertility services by transgender persons: an Ethics Committee opinion. Fertil Steril. 2015 Nov;104(5):1111–5.
7.
Condat A, Mendes N, Drouineaud V, Gründler N, Lagrange C, Chiland C, et al. Biotechnologies that empower transgender persons to self-actualize as individuals, partners, spouses, and parents are defining new ways to conceive a child: psychological considerations and ethical issues. Philos Ethics Humanit Med. 2018;13(1):1.PubMedPubMedCentral
8.
Mattawanon N, Spencer JB, Schirmer DA, Tangpricha V. Fertility preservation options in transgender people: a review. Rev Endocr Metab Disord. 2018;19(3):231–42.PubMed
9.
Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13(4):165–232.
10.
Moravek MB, Kinnear HM, George J, Batchelor J, Shikanov A, Padmanabhan V, et al. Impact of exogenous testosterone on reproduction in transgender men. Endocrinology. 2020;161(3):bqaa014.PubMed
11.
Neblett MF, Hipp HS. Fertility considerations in transgender persons. Endocrinol Metab Clin N Am. 2019;48(2):391–402.
12.
Wierckx K, Van Caenegem E, Pennings G, Elaut E, Dedecker D, Van de Peer F, et al. Reproductive wish in transsexual men. Hum Reprod. 2012;27(2):483–7.PubMed
13.
• Auer MK, Fuss J, Nieder TO, Briken P, Biedermann SV, Stalla GK, et al. Desire to have children among transgender people in Germany: a cross-sectional multi-center study. J Sex Med. 2018;15(5):757–67 Multicenter study evaluating both transmen and women before and after start of GAT and their respective desires to have children.PubMed
14.
15.
Jones CA, Reiter L, Greenblatt E. Fertility preservation in transgender patients. Int J Transgenderism. 2016;17(2):76–82.
16.
Wakefield BW, Boguszewski K, Cheney D, Taylor J. Trends in fertility preservation for transgender adolescents and young adults at an academic referral center. J Adolesc Health. 2018;62(2):S41.
17.
Chen D, Simons L, Johnson EK, Lockart BA, Finlayson C. Fertility preservation for transgender adolescents. J Adolesc Health. 2017;61(1):120–3.PubMedPubMedCentral
18.
Nahata L, Tishelman AC, Caltabellotta NM, Quinn GP. Low fertility preservation utilization among transgender youth. J Adolesc Health. 2017;61(1):40–4.PubMed
19.
Chen B, Zhang Z, Sun X, Kuang Y, Mao X, Wang X, et al. Biallelic mutations in PATL2 cause female infertility characterized by oocyte maturation arrest. Am J Hum Genet. 2017;101(4):609–15.PubMedPubMedCentral
20.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903.PubMed
21.
Moravek MB. Fertility preservation options for transgender and gender-nonconforming individuals. Curr Opin Obstet Gynecol. 2019;31(3):170–6.PubMed
22.
De Roo C, Tilleman K, T’Sjoen G, De Sutter P. Fertility options in transgender people. Int Rev Psychiatry. 2016;28(1):112–9.PubMed
23.
Padmanabhan V, Veiga-Lopez A. Animal models of the polycystic ovary syndrome phenotype. Steroids. 2013;78(8):734–40.PubMedPubMedCentral
24.
Shi D, Vine DF, et al. Fertil Steril. 2012;98(1):185–193.e2.PubMed
25.
•• Kinnear HM, Constance ES, David A, Marsh EE, Padmanabhan V, Shikanov A, et al. A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men. Hum Reprod. 2019;34(10):2009–17 Study evaluating effect of postpubertal T exposure on mice models to replicate GAT and fertility in transmale patients.PubMed
26.
Ikeda K, Baba T, Noguchi H, Nagasawa K, Endo T, Kiya T, et al. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Hum Reprod. 2013;28(2):453–61.PubMed
27.
Futterweit W, Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab. 1986;62(1):16–21.PubMed
28.
Chadha S, Pache TD, Huikeshoven FJM, Brinkmann AO, Van der Kwast TH. Androgen receptor expression in human ovarian and uterine tissue of long term androgen-treated transsexual women. Hum Pathol. 1994;25(11):1198–204.PubMed
29.
Grynberg M, Fanchin R, Dubost G, Colau J-C, Brémont-Weil C, Frydman R, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod BioMed Online. 2010;20(4):553–8.PubMed
30.
Nakamura A, Watanabe M, Sugimoto M, Sako T, Mahmood S, Kaku H, et al. Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. Endocr J. 2013;60(3):275–81.PubMed
31.
Steinle K. Hormonal management of the female-to-male transgender patient. J Midwifery Womens Health. 2011;56(3):293–302.PubMed
32.
T’Sjoen G, Van Caenegem E, Wierckx K. Transgenderism and Reproduction. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):575–9.PubMed
33.
• Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124(6):1120–7 Study detailing the effect of T exposure on pregnancy outcomes in transmales.PubMed
34.
Obedin-Maliver J, Makadon HJ. Transgender men and pregnancy. Obstet Med. 2016;9(1):4–8.PubMed
35.
Light A, Wang L-F, Zeymo A, Gomez-Lobo V. Family planning and contraception use in transgender men. Contraception. 2018;98(4):266–9.PubMed
36.
Matoso A, Khandakar B, Yuan S, Wu T, Wang LJ, Lombardo KA, et al. Spectrum of findings in orchiectomy specimens of persons undergoing gender confirmation surgery. Hum Pathol. 2018 Jun;76:91–9.PubMed
37.
Schneider F, Kliesch S, Schlatt S, Neuhaus N. Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function. Andrology. 2017;5(5):873–80.PubMed
38.
Hamada A, Kingsberg S, Wierckx K, T’Sjoen G, De Sutter P, Knudson G, et al. Semen characteristics of transwomen referred for sperm banking before sex transition: a case series. Andrologia. 2015;47(7):832–8.PubMed
39.
Adeleye AJ, Reid G, Kao C-N, Mok-Lin E, Smith JF. Semen parameters among transgender women with a history of hormonal treatment. Urology. 2019 Feb;124:136–41.PubMed
40.
Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HWG, Behre HM, et al. World Health Organization reference values for human semen characteristics*‡. Hum Reprod Update. 2010 Jan 1;16(3):231–45.PubMed
41.
Kim S-Y, Kim SK, Lee JR, Woodruff TK. Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women. J Gynecol Oncol. 2016;27(2):e22.PubMed
42.
Daar J, Benward J, Collins L, Davis J, Davis O, Francis L, et al. Planned oocyte cryopreservation for women seeking to preserve future reproductive potential: an Ethics Committee opinion. Fertil Steril. 2018;110(6):1022–8.
43.
De Sutter P. Gender reassignment and assisted reproduction. Hum Reprod. 2001;16(4):612–4.PubMed
44.
Wallace SA, Blough KL, Kondapalli LA. Fertility preservation in the transgender patient: expanding oncofertility care beyond cancer. Gynecol Endocrinol. 2014;30(12):868–71.PubMed
45.
Maxwell S, Noyes N, Keefe D, Berkeley AS, Goldman KN, et al. Obstet Gynecol. 2017;129(6):1031–4.PubMed
46.
Chen D, Bernardi LA, Pavone ME, Feinberg EC, Moravek MB. Oocyte cryopreservation among transmasculine youth: a case series. J Assist Reprod Genet. 2018;35(11):2057–61.PubMedPubMedCentral
47.
Armuand G, Dhejne C, Olofsson JI, Rodriguez-Wallberg KA. Transgender men’s experiences of fertility preservation: a qualitative study. Hum Reprod. 2017 Feb;32(2):383–90.PubMed
48.
•• Adeleye AJ, Cedars MI, Smith J, Mok-Lin E. Ovarian stimulation for fertility preservation or family building in a cohort of transgender men. J Assist Reprod Genet. 2019;36(10):2155–61 Effect of T exposure on ovarian stimulation outcomes in transmen vs cisgender women.PubMed
49.
Broughton D, Omurtag K. Care of the transgender or gender-nonconforming patient undergoing in vitro fertilization. Int J Transgenderism. 2017;18(4):372–5.
50.
•• Leung A, Sakkas D, Pang S, Thornton K, Resetkova N. Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine. Fertil Steril. 2019;112(5):858–65 Effect of T exposure on ovarian stimulation outcomes in transmen vs cisgender women.PubMed
51.
Cobo A, Garcia-Velasco JA, Domingo J, Remohí J, Pellicer A. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril. 2013;99(6):1485–95.PubMed
52.
Wierckx K, Elaut E, Van Hoorde B, Heylens G, De Cuypere G, Monstrey S, et al. Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med. 2014;11(1):107–18.PubMed
53.
Lee DE, Park SY, Lee SR, Jeong K, Chung HW. Diagnostic usefulness of transrectal ultrasound compared with transvaginal ultrasound assessment in young Korean women with polycystic ovary syndrome. J Menopausal Med. 2015;21(3):149–54.PubMedPubMedCentral
54.
Timor-Tritsch IE, Monteagudo A, Rebarber A, Goldstein SR, Tsymbal T. Transrectal scanning: an alternative when transvaginal scanning is not feasible: transrectal scanning. Ultrasound Obstet Gynecol. 2003;21(5):473–9.PubMed
55.
Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33(22):2424–9.PubMedPubMedCentral
56.
Katz DJ, Kolon TF, Feldman DR, Mulhall JP. Fertility preservation strategies for male patients with cancer. Nat Rev Urol. 2013;10(8):463–72.PubMed
57.
Kafetsoulis A, Brackett N, Ibrahim E, Attia G, Lynne C. Current trends in the treatment of infertility in men with spinal cord injury. Fertil Steril. 2006;86(4):781–9.PubMed
58.
Furuhashi K, Ishikawa T, Hashimoto H, Yamada S, Ogata S, Mizusawa Y, et al. Onco-testicular sperm extraction: testicular sperm extraction in azoospermic and very severely oligozoospermic cancer patients. Andrologia. 2013;45(2):107–10.PubMed
59.
Heger S, Müller M, Ranke M, Schwarz H-P, Waldhauser F, Partsch C-J, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol. 2006;254–255:217–20.PubMed
60.
Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, et al. Reversible inhibition of testicular Steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981;305(12):663–7.PubMed
61.
Rothenberg SS, Witchel SF, Menke MN. Oocyte cryopreservation in a transgender male adolescent. N Engl J Med. 2019;380(9):886–7.PubMed
62.
Insogna IG, Ginsburg E, Srouji S. Fertility preservation for adolescent transgender male patients: a case series. J Adolesc Health. 2020;66:750 S1054139X19309255.PubMed
63.
Har-Toov J, Brenner SH, Jaffa A, Yavetz H, Peyser MR, Lessing JB. Pregnancy during long-term gonadotropin-releasing hormone agonist therapy associated with clinical pseudomenopause. Fertil Steril. 1993;59(2):446–7.PubMed
64.
Fatima P, Hossain MM, Rahman D, Suman GM. Outcome of pregnancies after inadvertent exposure to GnRH agonist in early pregnancy. Mymensingh Med J MMJ. 2011;20(2):303–7.PubMed
65.
Donnez J, Dolmans M, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405–10.PubMed
66.
De Roo C, Lierman S, Tilleman K, Peynshaert K, Braeckmans K, Caanen M, et al. Ovarian tissue cryopreservation in female-to-male transgender people: insights into ovarian histology and physiology after prolonged androgen treatment. Reprod BioMed Online. 2017;34(6):557–66.PubMed
67.
Fasano G, Moffa F, Dechène J, Englert Y, Demeestere I. Vitrification of in vitro matured oocytes collected from antral follicles at the time of ovarian tissue cryopreservation. Reprod Biol Endocrinol. 2011;9(1):150.PubMedPubMedCentral
68.
Segers I, Mateizel I, Van Moer E, Smitz J, Tournaye H, Verheyen G, et al. In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. J Assist Reprod Genet. 2015 Aug;32(8):1221–31.PubMedPubMedCentral
69.
Lierman S, Tilleman K, Braeckmans K, Peynshaert K, Weyers S, T’Sjoen G, et al. Fertility preservation for trans men: frozen-thawed in vitro matured oocytes collected at the time of ovarian tissue processing exhibit normal meiotic spindles. J Assist Reprod Genet. 2017;34(11):1449–56.PubMedPubMedCentral
70.
Telfer EE. Future developments: in vitro growth ( IVG ) of human ovarian follicles. Acta Obstet Gynecol Scand. 2019;98(5):653–8.PubMed
71.
Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr. 2000;159(5):369–74.PubMed
72.
Liu PY, Turner L, Rushford D, McDonald J, Baker HWG, Conway AJ, et al. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum Reprod. 1999;14(6):1540–5.PubMed
73.
Picton HM, Wyns C, Anderson RA, Goossens E, Jahnukainen K, Kliesch S, et al. A European perspective on testicular tissue cryopreservation for fertility preservation in prepubertal and adolescent boys. Hum Reprod. 2015;30(11):2463–75.PubMed
74.
Chen D, Simons L. Ethical considerations in fertility preservation for transgender youth: a case illustration. Clin Pract Pediatr Psychol. 2018;6(1):93–100.PubMedPubMedCentral
75.
Hudson J, Nahata L, Dietz E, Quinn GP. Fertility counseling for transgender AYAs. Clin Pract Pediatr Psychol. 2018;6(1):84–92.PubMed
76.
Lyttle Schumacher B, Grover N, Mesen T, Steiner A, Mersereau J. Modeling of live-birth rates and cost-effectiveness of oocyte cryopreservation for cancer patients prior to high- and low-risk gonadotoxic chemotherapy. Hum Reprod. 2017;32(10):2049–55.PubMedPubMedCentral
77.
Kyweluk MA, Reinecke J, Chen D. Fertility preservation legislation in the United States: potential implications for transgender individuals. LGBT Health. 2019;6(7):331–4.PubMedPubMedCentral
78.
Gilbert K, Nangia AK, Dupree JM, Smith JF, Mehta A. Fertility preservation for men with testicular cancer: is sperm cryopreservation cost effective in the era of assisted reproductive technology? Urol Oncol Semin Orig Investig. 2018;36(3):92.e1–9.
79.
80.
Metadaten
Titel
Fertility Preservation for the Transgender Individual
verfasst von
Viji Sundaram
Evelyn Mok-Lin
Publikationsdatum
25.06.2020
Verlag
Springer US
Erschienen in
Current Obstetrics and Gynecology Reports / Ausgabe 3/2020
Elektronische ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-020-00291-z

Weitere Artikel der Ausgabe 3/2020

Current Obstetrics and Gynecology Reports 3/2020 Zur Ausgabe

Care for the Transgender Patients (C Ferrando, Section Editor)

Pelvic Pain in the Transgender Man

Endometriosis (P. Stratton, Section Editor)

A Proposed Platform for Phenotyping Endometriosis-Associated Pain: Unifying Peripheral and Central Pain Mechanisms

Care for the Transgender Patients (C Ferrando, Section Editor)

Care of the Post-vaginoplasty Patient: Management of Complications and Common Gynecologic Issues

Endometriosis (P. Stratton, Section Editor)

Long-Term Health Consequences of Endometriosis—Pathways and Mediation by Treatment

Ectopic Pregnancy (G Sel, Section Editor)

Ectopic Pregnancy Risk with Assisted Reproductive Technology

Family Planning (A Burke, Section Editor)

Interactions Between Hormonal Contraception and Anti-Retroviral Therapy: an Updated Review

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika
weitere anzeigen

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen